Parabilis Medicines, Inc. reported financial results and business updates for the third quarter ended September 30, 2026, disclosing updated clinical data for its lead candidate, zolucatetide. The company presented data from a June 22, 2026, data cut of its ongoing Phase 1/2 trial at the European Society for Medical Oncology (ESMO) Congress 2026. Among patients evaluable at the 32-week landmark who received a starting dose of 450 mg or greater, the objective response rate (ORR) was 72.2%, or 13 out of 18 patients. The disease control rate (DCR) was 100% across all 46 response-evaluable patients receiving the same starting dose, with no disease progression reported. The data also indicated a favorable safety and tolerability profile in 76 patients, with no treatment discontinuations due to treatment-related adverse events.
Parabilis announced that it has reached alignment with the U.S. Food and Drug Administration (FDA) on the dose, regimen, and trial design for the upcoming PEDESTAL Phase 3 registrational trial in desmoid tumors. The company plans to initiate this randomized, double-blind trial in the first half of 2027, with topline results anticipated in 2029. Additionally, Parabilis initiated a dose-ranging clinical study of zolucatetide in patients with familial adenomatous polyposis (FAP) and entered a clinical collaboration with Revolution Medicines. The collaboration will evaluate zolucatetide in combination with zoldonrasib and cetuximab for patients with previously treated RAS G12D mutant microsatellite stable metastatic colorectal cancer.
Regarding financial results, Parabilis ended the third quarter with $1.1 billion in cash, cash equivalents, and marketable securities. The company stated this cash position is expected to fund operations into 2030. For the quarter ended September 30, 2026, revenues were $2.1 million, primarily from collaboration agreements. Research and development expenses totaled $45.6 million, while general and administrative expenses were $11.3 million. The company reported a net loss of $44.5 million for the quarter.
